2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5505 A phase I/II study of azacitidine, venetoclax and olverembatinib for chronic myeloid leukemia in blast phase

Ying Wang, MD, Yan Hui2, Chengcai Guo3, Xiaoyuan Gong, MD4, Qiuyun Fang5, Zhenzhen Wang6, Chunlin Zhou7, Yang Miao8, Shaowei Qiu, MD9, Ying Wang, MD, PhD10, Yingchang Mi, MD11, Hui Wei, MD, PhD12, Jianxiang Wang Sr, MD, PhD13, Bingcheng LIU, MD14
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China

Introduction

The outcomes of patients (pts) with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP) have been greatly improved by the implementation of tyrosine kinase inhibitors (TKIs). However, pts with blast phase (BP)-CML, though now accounting for less than 5% of all CML cases, still face a dismal prognosis and represent a high unmet medical need. Hence, we designed a study to evaluate the safety and efficacy of a novel combination of azacitidine (AZA), venetoclax (VEN) and the third-generation BCR::ABL1 TKI olverembatinib in BP-CML.

Methods:

This single-center, single-arm, phase 1/2 study enrolled pts aged ≥15 years with t(9;22)(q34;q11)/BCR::ABL-positive BP-CML (as defined by WHO 2022 and ICC 2022), including both de novo BP and cases progressing from CP/AP. Exclusion criteria included prior BP-CML therapy (except single-agent TKI, glucocorticoids, hydroxyurea, or olverembatinib ≤14 days), extramedullary infiltration, myocardial infarction within 1 year, other clinically significant cardiac disease, acute pancreatitis within 1 year, or chronic pancreatitis history.Pts received olverembatinib (40mg QOD) + AZA (75 mg/m², D1–7) + VEN as induction. Post-remission, they underwent allogeneic hematopoietic stem cell transplant (HSCT) or continued olverembatinib + VEN (400 mg, D1–7) + AZA for consolidation/maintenance. Non-responders after 2 cycles were withdrawn.The phase 1 dose-escalation followed a 3+3 design to determine the maximum tolerated dose (MTD) of VEN (400 mg, 7/14/21 days) +AZA+olverembatinib in induction cycle.If BCR::ABL1 undetectable, olverembatinib reduced to 30 mg every other day. Phase 2 primary endpoint: hematological response rate (CHR) after 2 cycles. This trial was registered with ClinicalTrials.gov (NCT06757855).

 

Results:

From February 2024 to June 2026, 20 pts were enrolled (4 de novo BP, 16 progressed from CP/AP). The median age was 43.6 years (16-62 years), with a male proportion of 60%. For the 16 pts who had progressed from CML-CP/AP, the median time to CML-BP was 46.6 months (1-184 months), 9 pts (45%) received 1 prior TKI, 6 pts(30.0%) received 2, and 1 pts (5.0%) received 3. Blasts phenotype was myeloid in 10 pts (50.0%) and lymphoid in 10 pts (50.0%). All 20 pts were positive for BCR::ABL1 p210 transcript. Ten pts (50.0%) had an ACA, and two pts (10%) had an CCA. At study entry, ABL kinase domain mutations were detected in 50% (10/20) of pts, including concurrent E255K/F486S/G250E/E255V/E459K in one patient, concurrent E255K/T315I in one patient, E255K alone in three patients, and single mutations (E189K, E355G, H396R, Y253F and Y253H) in 1 patient each. Next-generation sequencing demonstrated that the most common mutations were RUNX1 (n=4), ASXL1(n=2), GATA2 (n=2), SBDS(n=2) and BCORL1 (n=2).

The hematological responses were evaluable in 20 pts after 1 cycle, CR 30.0% (6/20), CR/CRh/CRi 60.0% (12/20), MLFS 20.0% (4/20), PR 5.0% (1/20), and NR 15.0% (3/20). After cycle 1, 2 pts proceeded to HSCT, 1 discontinued due to elevated creatinine; and 1 had not yet begun cycle 2. Of the 16 evaluable pts after 2 cycles, response rates were: CR 37.5%(6/16), CR/CRh/CRi 68.8% (11/16), MLFS 18.8% (3/16), and NR 12.5% (2/16). The best cytogenetic responses were CCyR in 15 patients (75%), PCyR in 1 patient (5%), MiniCyR in 2 patients (10%), and not evaluable in 2 patients (10%). The best molecular responses in 20 patients were: CMR in 2 (10%), MMR in 6 (30%), MR2 in 4 (20%), and no response in 8 (40%). 12 of 20 pts (60%) were bridged to HSCT; the median time from diagnosis of CML-BP to HSCT was 101.8 days (65-177 days). At a median follow-up of 202.5 days (57 to 492 days), the 1-year OS rate was 100%.

The main adverse events were hematologic toxicities, with grade 3/4 neutropenia in 19(95%) pts and grade 3/4 thrombocytopenia in 16 (80%) pts. Among responding pts during cycle 1, the median time to an absolute neutrophil count >1× 109/L was 26.9 days (9-39), the median time to a platelet count > 100× 109/L was 18.2 days (0-47). Only one patient developed intermuscular venous thrombosis, and no other thromboembolic events were observed.

Conclusion

BP-CML is associated with poor prognosis under current therapeutic approaches. Our study demonstrated high rates of bone marrow remission, cytogenetic and molecular responses and safety profile with combination of AZA, VEN and olverembatinib in CML-BP pts. Further studies warranted to validate this regimen.

Ying Wang, MD: No relevant conflicts of interest to declare.